Mariathasan et al. showed that therapeutic co-administration of TGFβ-blocking galunisertib and anti-PD-L1 antibodies reduced TGFβ signaling in stromal cells, facilitated T-cell penetration into the center of tumors, and provoked vigorous anti-tumor immunity and tumor regression (6). This evidence concerns the gene TGFB1 and neoplasm.